Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
Clinical trial NCT07714317 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07714317
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-20
- Primary completion
- 2027-07-31
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.